Tim Boreham is an experienced business writer, with over three decades at major business publications – covering sectors including; banking, accounting (really, it’s not boring), resources, technology, telecoms, agribusiness, property trusts and — of course — life sciences.
Tim was best known as writer of The Australian’s Criterion investment column, which analysed listed companies — both large and small — in a way that was accessible to retail investors.
Proudly sponsored by Independent Investment Research, Criterion is now The New Criterion and appears weekly in publications including TheAustralian’s Wealth section, The Constant Investor, Sharecafe, Livewire, Switzer News and The Rub
Tim’s weekly column on biotech stocks Dr. Boreham’s Crucible appears in Biotech Daily and the small-caps website Stockhead
From February 2018, all articles can be accessed on this site
Tim can be contacted at email@example.com